Amneal launches authorized generic for xyrem® (sodium oxybate) and receives fda approval for five complex generics in the second quarter

Bridgewater, n.j.--(business wire)--amneal pharmaceuticals, inc. (nyse: amrx) (“amneal” or the “company”) today announced the launch of its authorized generic for xyrem®1 (sodium oxybate) oral solution ciii in the united states. sodium oxybate oral solution, 0.5 g/ml is a central nervous system depressant indicated for the treatment of cataplexy or excessive daytime sleepiness (eds) in patients seven years of age and older with narcolepsy. in addition, the company announced it has received abbr.
AMRX Ratings Summary
AMRX Quant Ranking